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Key points:  
  
• 20% of community-based Australian adolescents with intellectual disability in this 
study used psychotropic medications. 
• Psychotropic medication use was strongly associated with male gender and the 
presence of major behaviour problems.  
• Further studies examining the rationale for psychotropic prescribing in adolescents 
with intellectual disability are needed.  
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Abstract  
Purpose. Information on the use of psychotropic medications in adolescents with intellectual 
disability is scant. Such information can guide interventions to improve psychotropic 
medication use in this population. We investigated the prevalence of, and factors associated 
with, psychotropic medication use in adolescents with intellectual disability in Australia who 
live in the community.  
Methods. Cross-sectional data were obtained from adolescents with intellectual disability 
living in the community in South-East Queensland, Australia, between February 2007 and 
September 2010. Self-reported information on medication use was extracted from a health 
screening tool. Demographic and medical data were collected through parent/caregiver 
surveys. Medications were classified according to the Anatomical Therapeutic Chemical 
classification system. Psychopathology was assessed using the Developmental Behaviour 
Checklist Short Form. Logistic regression analysis was used to assess the association of 
demographic and medical characteristics with psychotropic medication use.     
Results. There were 176 participants (median age=16 years, range=11-19 years; 55% male). 
Psychotropics were used by 20% of participants. Psychostimulants were the commonest 
psychotropic class, used by 9% of participants. Multipsychotropic prescribing was not 
common with only seven participants using more than one psychotropic agent. After adjusting 
for potentially confounding variables, use of psychotropic medications was significantly 
associated with male gender (adjusted odds ratio=3.6; 95% confidence interval=1.3-9.5) and 
having major behaviour problems (3.1; 1.1-8.9).  
Conclusions. Adolescents with intellectual disability use a wide range of psychotropic 
medications. Being male and having major behaviour problems are associated with use of 
psychotropic medications. Research examining the rationale for psychotropic prescribing in 
this population is needed. 
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Introduction  
The prevalence and patterns of prescription of medications in people with intellectual 
disability vary considerably; however, the consensus view is that people with intellectual 
disability are among the most medicated populations residing in either institutions or the 
community.1-3 Most of the existing literature considering medication use in people with 
intellectual disability has investigated use in adults only or combined data on medication use 
in both adults and children. Little is known about the magnitude of, and factors associated 
with, medication use in adolescents with intellectual disability.  
Adolescents with intellectual disability are characterised by a high prevalence of psychiatric 
disorders and behaviour problems compared with their typically developing peers.4,5 
Psychotropic medications have been widely used to treat psychopathological conditions in 
this population.6  However, their use remains controversial due to limited empirical efficacy 
data and potential deleterious adverse effects such as tardive dyskinesia, akathisia, and/or 
extrapyramidal symptoms.6 As such, the widespread use of psychotropic medications in 
adolescents with intellectual disability has become a major concern of healthcare planners 
worldwide.6,7 Without an understanding of how psychotropic medications are being 
prescribed in this population, suggesting measures to improve the quality use of these 
medications is difficult. To date, there are only three medication use studies focusing on 
adolescents with intellectual disability.8,9,10 These studies have discrepant results. Two studies 
were conducted in the Netherlands - a 2005 study of 912 individuals8 and a 2006 study of 862 
individuals9 aged 4 to 18 years of all levels of intellectual disability who lived both in the 
community and institutions. Both studies reported 10% of the sample used psychotropics.8,9 A 
more recent population-based study of 1419 Taiwanese adolescents (aged 12 to 17 years) 
living both in the community and institutions found 24% of adolescents used prescribed 
medications on a regular basis.10 These studies suggested the need for additional research to 
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provide further insight into the use of medications, especially psychotropic medications in 
these vulnerable populations. This study endeavours to address this need by investigating the 
prevalence of, and factors associated with, psychotropic medication use in community-based 
Australian adolescents with intellectual disability.  
Methods  
We investigated a sample of adolescents with intellectual disability living in the community 
in South-East Queensland, Australia, between February 2007 and September 2010. The data 
reported were derived from a large randomised controlled trial investigating the effectiveness 
of a health intervention package in improving the long-term health of adolescents with 
intellectual disability.11 Trial participants were adolescents with intellectual disability aged 10 
to 18 years who were receiving education either in a special education school (SES) or in a 
special education unit (SEU) on the campus of a secondary school. In Queensland, students 
receiving education in a SES have significant intellectual disabilities and/or multiple 
disabilities. They usually require specialist teaching and therapy services that facilitate an 
individualised education program. Students attending a SEU in a primary or secondary school 
may have a range of disabilities, and usually access the mainstream curriculum and receive 
specialist teaching and therapy services. The trial was approved by both The University of 
Queensland Behavioural and Social Sciences Ethical Review Committee (Clearance number: 
2004000081) and the Queensland Government Department of Education and the Arts (File 
number: 550/27/424).  
The health intervention package employed in the trial consisted of two main components: the 
Ask (Advocacy Skills Kit) Health Diary and the Comprehensive Health Assessment Program 
(CHAP). The Ask Health Diary is a personalised hand-held health record. The CHAP is a one-
off health check. It is partially completed by the adolescent with intellectual disability and 
their parent/caregiver prior to a general practitioner (GP) consultation, and includes a self-
5 
 
reported health history of the adolescent including all medications used. The CHAP is 
completed by the GP during the consultation. After each GP assessment, the CHAP booklet 
was returned to the research team. The Ask Health Diary,12 the CHAP13 and the trial11 have 
been comprehensively described previously. 
We used the self-reported medication data from completed and returned CHAP booklets. 
Medications were classified according to the Anatomical Therapeutic Chemical (ATC) 
classification system developed by the World Health Organization for medication utilisation 
research.14 The ATC system groups medications into categories according to the organ or 
system on which they act and/or their chemical, pharmacological and therapeutic 
characteristics.14 For medications that could be classified into several categories, 
determination of the ATC category was based on the purpose of the pharmacotherapy and the 
medical history of the adolescent. Psychotropic medications were defined as medical agents 
for the central nervous system, excluding analgesics and anticonvulsants.9 They included 
antipsychotics, antidepressants, anxiolytics, anti-Parkinson medications, hypnotics/sedatives, 
alpha2-agonists (clonidine and guanfacine) and atomoxetine.9 On two occasions where 
prescribing information from the CHAP booklet was unclear, medical records were accessed 
to confirm the information. Data on age, gender, school type, level of mobility and health 
status were derived from baseline surveys completed by the adolescents’ parents/caregivers at 
the commencement of the trial. Information regarding the presence/absence of epilepsy, 
Down syndrome and autistic spectrum disorder was obtained from the CHAP booklets. Body 
Mass Index (BMI, weight/height2) calculations were based on the heights and weights 
recorded by the GP in the CHAP. We used age- and gender-specific BMI cut-offs for children 
and adolescents reported by Cole et al.15 for overweight and obesity and by Cole et al.16 for 
underweight.  
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Psychopathology was assessed using the Developmental Behaviour Checklist Short Form 
(DBC-P24)17 developed from the 96-item Developmental Behaviour Checklist (DBC-
P).18 The DBC-P24 consists of 24 items concerning emotional and behaviour disturbance 
frequently observed in children and adolescents aged 4 to 18 years with intellectual 
disability.17 Parents/caregivers reported the presence of each of the 24 items in their child for 
the past six months on a three-point scale: “very true or often true” (score of 2), “somewhat or 
sometimes true” (score of 1), or “not true” (score of 0).17 Mean behaviour problem scores 
were calculated as the sum of responses to the 24 items divided by the total number of items 
each parent/caregiver answered.17 Participants with a mean score of 0.48 or higher were 
considered to have evidence of behaviour problems.17 This cut-off point was determined by 
assessing the checklist’s ability to classify individuals with and without behaviour problems 
over a range of behaviour problem scores, which was quantified by using the Receiver 
Operating Characteristics curve.18 The curve was a plot of the true positive rate against the 
false positive rate of the checklist at each threshold setting.18 The optimal cut-off point was 
where the true positive rate was highest and false positive rate was lowest.18 This 
corresponded to the cut-off point of 0.48 for the DBC-P24.17 The higher the score, the more 
severe behaviour problems the participants had.17,18 The DBC-P and DBC-P24 have been 
demonstrated to have very good sensitivity and specificity in classifying cases with and 
without behaviour problems.17,18 Einfeld and Tonge18 and Taffe et al.17 described in detail 
how the DBC-P and DBC-P24 were developed and how the cut-off point was determined. To 
more usefully categorise participants we calculated the median of mean behaviour problem 
scores for all participants with behaviour problems (i.e. mean behaviour problem scores ≥ 
0.48), which allowed us to examine the effect of behaviour problems in more detail. The 
value of this median was 0.75. In doing so, the data set was divided approximately into thirds. 
The lowest third included non-behaviour problem cases (i.e. mean behaviour problem scores 
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< 0.48); the middle third included minor behaviour problem cases (i.e. mean behaviour 
problem scores ≥ 0.48 but < 0.75); and the highest third included major behaviour problem 
cases (i.e. mean behaviour problem scores ≥ 0.75). Participants in the third tertile had 
behaviour-associated problems that were more obvious and happened more frequently than 
those in the second tertile.  
We computed the prevalence of medication use, and investigated the associations between 
variables of interest and the use of psychotropic medications by computing unadjusted odds 
ratios as well as adjusting for potentially confounding variables using logistic regression 
analysis. Variables examined were: gender, school type, weight classification, self-reported 
health status, self-reported level of mobility, and the presence/absence of behaviour problems, 
epilepsy, Down syndrome and autistic spectrum disorder. Analyses were conducted using 
Stata statistical software version 11 (StataCorp, College Station, TX, USA). 
Results  
One hundred and one schools were approached, of which 85 agreed to participate in the trial. 
At baseline there were 728 participants, 425 of whom were randomised to receive the health 
intervention package; of these, 176 completed and returned the CHAP booklets. Adolescents 
who completed and returned the CHAP booklets were similar to those who did not in terms of 
gender (55% male versus 53%); age (median(range)=16(11-19 years) versus 16(12-22 
years)); school type (55% SES versus 56%); and mean behaviour problem score 
(median(interquartile range)=0.63(0.39-0.88) versus 0.70(0.42-0.88)). All participants 
included in the present study lived with their parents or caregivers. Characteristics of 
participants are presented in Table 1; 96 (55%) attended a SES, 150 (85%) reported their level 
of mobility as being completely independent and 33 (19%) reported they had epilepsy. The 
median value of the mean behaviour problem scores for adolescents with behaviour problems, 
which was used to separate minor and major behaviour problems, was 0.75. There were 62 
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(35%) adolescents who did not have behaviour problems; 58 (33%) who had minor behaviour 
problems and 55 (31%) who had major behaviour problems. 
[Insert Table 1 here] 
Thirty six (20%) participants were using psychotropic medications (Table 2). 
Multipsychotropic regimens were administered to seven (4%) participants. The commonest 
combination of psychotropics was an atypical antipsychotic (risperidone) and a selective 
serotonin reuptake inhibitor (SSRI) antidepressant (citalopram or sertraline). Participants who 
received this combination had major behaviour problems, abnormal weight, autistic spectrum 
disorder, were male and received education in a SES. Psychostimulants were the commonest 
psychotropic class (used by 9% of the total sample), followed by antidepressants (6%) and 
antipsychotics (5%). Other psychotropic classes (alpha2-agonists, anti-Parkinson medications, 
hypnotics/sedatives) were used infrequently. The association between characteristics of 
interest and psychotropic medication use is displayed in Table 1. Gender and behaviour 
problems were significantly associated with the use of psychotropic medications. Male 
participants were 3.6 times more likely to take psychotropic medications than female 
participants (adjusted odds ratio [AOR]=3.6; 95% confidence interval [95% CI]=1.3-9.5). 
Participants with major behaviour problems were 3.1 times more likely to use psychotropic 
medications than those without major behaviour problems (AOR=3.1; 95% CI=1.1-8.9).  
[Insert Table 2 here] 
Anticonvulsants were taken by 27 (15%) participants; 26 (96%) of whom were reported by 
their parent/caregiver to have epilepsy. Of those taking anticonvulsants, 59% were receiving 
one anticonvulsant agent, 30% two and 11% three. Among anticonvulsants, valproate was the 
most frequently prescribed agent (used by 55% of participants taking anticonvulsants), 
followed by lamotrigine (37%), carbamazepam (22%), topiramate (15%), levetriacetam (7%), 
clonazepam and vigabatrin (4% each).  
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Discussion  
A range of medications was administered to this sample of adolescents with intellectual 
disability. Psychotropics and anticonvulsants were prescribed for 20% and 15% of 
participants respectively. Psychotropic medications were used more by males than females. 
This may be in part explained by a higher prevalence of psychiatric disorders observed in 
male participants compared with their female counterparts (25% males versus 6% females had 
autistic spectrum disorder, 63% versus 49% had behaviour problems). In addition, males may 
experience more severe symptoms of a psychiatric disorder than females with the same 
diagnosis.19 Studies examining the association between gender and psychotropic medication 
use in people with intellectual disability are limited; however, this gender disparity in 
psychotropic medication use is consistent with findings from existing publications relating to 
typically developing children and adolescents.20,21 Participants with major behaviour problems 
used more psychotropic medications than those without behaviour problems, consistent with 
previous studies.9,22 This suggests psychotropics were prescribed for this population either to 
control or treat behaviour problems. The associations between psychotropic medication use 
and autistic spectrum disorder and epilepsy became insignificant after adjustment for 
confounding factors. The insignificant association between psychotropic medication use and 
autistic spectrum disorder may be explained by the fact that the condition usually manifests as 
behaviour problems.23,24 Although epilepsy is prevalent in this patient population, it is treated 
by using anticonvulsants, rather than psychotropic medications.3  
In their review of pharmacoepidemiology of intellectual disability using data from studies 
undertaken from 1986 to 1995, Singh et al.25 reported 19-29% of children and adults with 
intellectual disability living in the community used psychotropic medications. We observed 
20% of participants used these medications, within the range reported by Singh et al.25 
However, this prevalence is higher than the 10% reported by Tobi et al.8 and de Bildt et al.9 in 
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children and adolescents aged 4 to 18 years with intellectual disability in the Netherlands. The 
20% prevalence of psychotropic medication use observed in our study is lower than the 
figures reported in adults with intellectual disability who live in the community in Australia 
(35%)26 or internationally (34-37%).2,27 These differences in the prevalence of psychotropic 
medication use highlight the effect that different sample frames can have on estimates of 
prevalence of medication use. The present study supplements the limited population-level 
knowledge that exists and suggests that, overall, Australian adolescents with intellectual 
disability are twice as likely to be prescribed psychotropic medications as their Dutch peers. 
However, most of the prescribing occurs in individuals with major behaviour problems.  
Our study is the first to investigate medication use in adolescents with intellectual disability in 
Australia. The 176 participants shared similar demographic and behaviour characteristics with 
participants who were randomised to receive the CHAP, but did not return their CHAP 
booklets to the research team. This suggests participants are likely to be a representative 
sample of Australian adolescents with intellectual disability, and that these results are 
generalisable to other Australian adolescents with intellectual disability. The study does have 
some limitations; most notably was self-reported medication usage information, potentially 
resulting in recall and information biases. However, previous studies have shown a high 
concordance between self-reported medication data and official prescription database.28,29 
Another limitation stemmed from the ATC classification system. The system classifies 
medications based on their main therapeutic use.14 However, medications can have more than 
one indication, and it is sometimes difficult to know the indication for which a medication 
was prescribed. Nevertheless, the system has been demonstrated to be suitable for medication 
use research.30 We were unable to investigate the association between the severity of 
intellectual disability and psychotropic medication use due to the lack of data. Some studies 
found the use of psychotropic mediations increases with level of intellectual disability in both 
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adolescents8,10 and adults31 with intellectual disability; whereas others reported no 
association.9,27 
Data on psychotropic medication use from the general Australian population are limited. It is 
estimated that 5% of Australian adolescents aged 15 to 19 years and 11% of the general 
Australian population aged 15 years and older use psychotropic medications.32 In the present 
study, 20% of participants used these medications. Given that psychopathological disorders 
are more prevalent in adolescents with intellectual disability compared with the general 
population,4,5 it is unsurprising that the former reported more psychotropic medications than 
the latter.   
Antidepressant use in the treatment of depression and anxiety disorders in children and 
adolescents has changed dramatically over the past decade.6 The most notable change is the 
replacement of tricyclic antidepressants with SSRIs, which have fewer side effects.6,33 We 
found the most commonly used antidepressants were SSRIs, reflecting this trend. Tricyclic 
antidepressants were prescribed for four participants. Although there is no evidence 
supporting the use of tricyclic antidepressants in treating depression in children and 
adolescents,34 they remain an evidence-based treatment for obsessive-compulsive disorder 
and a second-line treatment for attention deficit hyperactivity disorder in these populations.35 
Australian therapeutic guidelines recommend ‘the choice of SSRI for adolescents should be 
made taking into account the recent evaluations of clinical trial data and product information’ 
(page 777); and current Australian product information for SSRIs recommends against their 
use in children and adolescents.36 Given that psychiatric and behaviour problems are 
overrepresented in children and adolescents with intellectual disability,4,5 antidepressants may 
be still useful for these populations. In addition, it is possible that antidepressants are seen by 
prescribers as efficacious in treating emotional lability and obsessionality in children and 
adolescents with severe intellectual disability.37 
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Co-prescribing was a common practice, with 44% of participants using more than one 
medication. People with intellectual disability usually have a wide range of health 
problems,38,39 therefore polypharmacy may be appropriate. However, careful monitoring of 
potentially harmful drug interactions must be exercised when combination therapy is 
employed, especially within the cytochrome P450 isoenzyme system where many 
medications and most psychotropic medications are metabolised.6 Given there have been 
cases of potentially fatal serotonin syndrome caused by serotonergic medication combinations 
in children,40 prescribers must be aware of the pharmacological effects of medications. The 
use of psychotropic medications to treat psychiatric and behaviour problems in children and 
adolescents with intellectual disability is based on extrapolation of adult data.6 Such 
extrapolation is problematic because psychopathology and pharmacology of medications may 
be expressed differently in children and adolescents with intellectual disability compared with 
their adult counterparts and the general population.3,6  
In summary, a range of psychotropic medications was administered to adolescents with 
intellectual disability. Evidence to support psychotropic use in this population is currently 
insufficient. Well-designed clinical trials of safety and efficacy of psychotropic medications 
in adolescents with intellectual disability are needed. Research examining the rationale for 
prescribing in this population is desirable.  
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Table 1. Association of psychotropic use with demographic and medical variables (N=176) 
Variable N n  (%) Unadjusted 
 OR (95% CI) 
Adjusted* OR  
(95% CI) 
p-value** 
Gender      
Female 79 8 (10) 1.0 1.0  
Male 97 28 (29) 3.6 (1.5-8.5) 3.6 (1.3-9.5) 0.011 
School type       
Special education unit 80 14 (18) 1.0 1.0  
Special education school  96 22 (23) 1.4 (0.7-3.0) 1.0 (0.4-2.6) 0.944 
Weight classification***      
Normal 75  15 (20) 1.0 1.0  
Underweight  25  6 (24) 1.3 (0.4-3.7) 1.0 (0.3-3.4) 0.974 
Overweight 33 7 (21) 1.1 (0.4-3.0) 1.0 (0.3-3.4) 0.939 
Obese  35  7 (20) 1.0 (0.4-2.7) 1.3 (0.4-4.2) 0.669 
Self-reported health status       
Excellent/very good 111  18 (16) 1.0 1.0  
Good/fair/poor  65  18 (28) 2.0 (0.9-4.2) 1.8 (0.7-4.4) 0.220 
Self-reported level of mobility       
Completely independent 150  29 (19) 1.0 1.0  
Other† 26  7 (27) 1.5 (0.6-4.0) 1.4 (0.4-4.4) 0.618 
Behaviour problemsǂ      
No behaviour problems  62  9 (15) 1.0 1.0  
Minor behaviour problems  58  6 (10) 0.7 (0.2-2.0) 0.7 (0.2-2.5) 0.605 
Major behaviour problems  55 21 (38) 3.6 (1.5-8.9) 3.1 (1.1-8.9) 0.035 
Epilepsy      
No 143  24 (17) 1.0 1.0  
Yes 33  12 (36) 2.8 (1.2-6.5) 1.5 (0.5-4.1) 0.461 
Down syndrome§        
No 148  34 (23) 1.0 1.0  
Yes 26  2 (8) 0.3 (0.1-1.2) 0.4 (0.1-2.4) 0.332 
Autistic spectrum disorder      
No 143  23 (16) 1.0 1.0  
Yes 33  13 (39) 3.0 (1.3-7.1) 1.6 (0.6-4.4) 0.340 
Abbreviations: OR, odds ratio; CI – confidence interval.  
*Associations were adjusted for gender, school type, weight classification, self-reported health status, self-
reported level of mobility, the presence/absence of behaviour problems, epilepsy, Down syndrome and autistic 
spectrum disorder.  
**p-value for adjusted odds ratios  
***Missing data for 8 participants.  
†Independent but may use aids, walks with help, uses wheelchair independently, uses wheelchair with 
assistance, immobile.  
ǂMissing data for 1 participant. A cut-off point of mean behaviour problems scores of 0.48 was used to separate 
participants with and without behaviour problems. A cut-off point of mean behaviour problems scores of 0.75 
was used to separate participants with minor and major behaviour problems.  
§Missing data for 2 participants.  
 
 
 
 
 
 
 
 
14 
 
Table 2. Prevalence of medication use (N=176) 
Medication category ATC code n   % 
All categories of medications   120 68 
Psychotropics  36 20 
Psychostimulants  N06B 16 9 
Antidepressants N06A 11 6 
Selective serotonin reuptake inhibitor   7  
Tricyclic   4  
Antipsychotics N05A 9 5 
Typical   1  
Atypical   8  
Anxiolytics  N05B 4 2 
Alpha2-agonists (clonidine) N02CX02 3 2 
Anti-Parkinson medications N04 1 1 
Hypnotics/sedatives  N05C 1 1 
Anticonvulsants  N03A 27 15 
Analgesics and anti-inflammatory medications N02/M01A 44 25 
Anti-asthmatics*   R03 23 13 
Sex hormones and modulators of the genital system G03 14 8 
Corticosteroids (dermatological preparations)  D07 11 6 
Anti-histamines for systemic use R06 9 5 
Cough and cold preparations R05 8 5 
Laxatives A06 7 4 
Antimicrobials for systemic use J01/J02 6 3 
Beta-blockers and angiotensin converting enzyme inhibitors C07/C09 3 2 
Other**, not elsewhere classified  42 24 
Abbreviations: ATC, Anatomical Therapeutic Chemical. 
*Used as pro re nata. 
 **Medications for acid-related disorders (A02), antineoplastics (L01), muscle relaxants (M03), urinary 
antispasmodics (G04BD) and thyroid hormones (H03).  
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